Domov › Akútna myeloidná leukémia › Wisconsin

Klinické štúdie Akútna myeloidná leukémia v štáte Wisconsin

25 štúdií pre Akútna myeloidná leukémia hľadá účastníkov v zariadeniach v štáte Wisconsin.

Mestá v štáte Wisconsin

Oficiálny text štúdie (anglicky)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Gundersen Lutheran Medical Center, La Crosse

Prebieha náborFáza 2

Vek 60 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
ThedaCare Regional Cancer Center, Appleton
ThedaCare Regional Medical Center - Appleton, Appleton
a 50 ďalších

Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov

Vek 40 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Children's Hospital of Wisconsin, Milwaukee

Prebieha náborObservačná štúdia

Vek 0 až 38 · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06131801

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

ThedaCare Regional Cancer Center, Appleton
ThedaCare Regional Medical Center - Appleton, Appleton
Duluth Clinic Ashland, Ashland
a 6 ďalších

Prebieha náborFáza 2

Vek 18 až 59 · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

ThedaCare Regional Cancer Center, Appleton
Duluth Clinic Ashland, Ashland
Aurora Cancer Care-Southern Lakes VLCC, Burlington
a 41 ďalších

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

ThedaCare Regional Cancer Center, Appleton
Duluth Clinic Ashland, Ashland
Saint Vincent Hospital Cancer Center Green Bay, Green Bay
a 11 ďalších

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Duluth Clinic Ashland, Ashland
Saint Vincent Hospital Cancer Center Green Bay, Green Bay
Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
a 9 ďalších

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

ThedaCare Regional Cancer Center, Appleton
ThedaCare Regional Medical Center - Appleton, Appleton
Duluth Clinic Ashland, Ashland
a 8 ďalších

Prebieha náborFáza 2

Vek 18 až 59 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Saint Vincent Hospital Cancer Center Green Bay, Green Bay
University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Marshfield Medical Center-Marshfield, Marshfield
a 1 ďalších

Prebieha náborFáza 3

6 Months – 21 Years · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT04293562

A Study of BGB-11417 in Participants With Myeloid Malignancies

Medical College of Wisconsin, Milwaukee

Prebieha náborFáza 1/2

Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT04771130

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Saint Vincent Hospital Cancer Center Green Bay, Green Bay
University of Wisconsin Carbone Cancer Center - University Hospital, Madison

Prebieha náborFáza 3

Vek 1 až 25 · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Marshfield Medical Center-Marshfield, Marshfield

Prebieha náborFáza 1/2

Do veku 22 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04726241

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

University of Wisconsin, Madison
Froedtert & Medical College of Wisconsin, Milwaukee

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 8. 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Froedtert & Medical College Clinics, Milwaukee

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 8. 2026 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Medical College of Wisconsin, Milwaukee

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 8. 2026 · NCT06656494

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

University of Wisconsin - Madison, Madison
Children's Hospital of Wisconsin, Milwaukee

Prebieha náborObservačná štúdia

Všetky vekové kategórie · Všetky pohlavia · Aktualizované 6. 7. 2026 · NCT01351545

Ivosidenib as Post-HSCT Maintenance for AML

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

Prebieha náborFáza 2

Vek 18 až 75 · Všetky pohlavia · Aktualizované 18. 6. 2026 · NCT06707493

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

University of Wisconsin Carbone Cancer Center, Madison

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 5. 2026 · NCT06222580

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Froedtert & Medical College of Wisconsin, Milwaukee

Prebieha náborFáza 2/3

Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 4. 2026 · NCT04256317

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

University of Wisconsin Carbone Cancer Center, Madison

Prebieha náborFáza 1

Do veku 21 · Všetky pohlavia · Aktualizované 22. 4. 2026 · NCT05101551

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

University of Wisconsin Hospital and Clinics, Madison
Medical College of Wisconsin Cancer Center, Milwaukee

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 3. 2026 · NCT05735184

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Children's Wisconsin, Milwaukee

Prebieha náborFáza 1

Vek 1 až 25 · Všetky pohlavia · Aktualizované 12. 1. 2026 · NCT05317403

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

University of Wisconsin Carbone Cancer Center, Madison

Prebieha náborFáza 1

7 Months – 21 Years · Všetky pohlavia · Aktualizované 16. 10. 2025 · NCT02508038

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

University of Wisconsin Clinical Science Center, Madison

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2025 · NCT06501196

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

University of Wisconsin, Madison

Prebieha náborVítaní zdravých dobrovoľníkov

Vek 18 až 120 · Všetky pohlavia · Aktualizované 25. 7. 2025 · NCT05237258

Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.